Takashi Yamanaka - Publications

Correction: Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017.

Journal: Breast cancer (Tokyo, Japan)

Published: May 29, 2026

Trastuzumab deruxtecan rechallenge in HER2-positive metastatic breast cancer: EN-SEMBLE.

Journal: Breast (Edinburgh, Scotland)

Published: April 20, 2026

Primary tumour resection reduces the risk of major local morbidity in de novo stage IV breast cancer: secondary data analysis from the JCOG1017 randomized controlled trial.

Journal: The British journal of surgery

Published: March 21, 2026

Clinicopathological predictors of distant recurrence in breast cancer patients achieving pathological complete response after neoadjuvant chemotherapy.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: January 10, 2026

Safety and effectiveness of post-trastuzumab deruxtecan regimens in patients with HER2-positive metastatic breast cancer who discontinued trastuzumab deruxtecan due to interstitial lung disease.

Journal: Breast (Edinburgh, Scotland)

Published: December 18, 2025

Prospective observational study of atezolizumab plus nab-paclitaxel in patients with metastatic triple-negative breast cancer: JBCRG-C08/ATTRIBUTE.

Journal: NPJ breast cancer

Published: November 03, 2025

Olanzapine for nausea and vomiting in people with breast cancer treated with trastuzumab deruxtecan: plain language summary of the ERICA study.

Journal: Future oncology (London, England)

Published: October 24, 2025

Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial.

Journal: Breast cancer (Tokyo, Japan)

Published: September 16, 2025

Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.

Journal: Breast cancer research and treatment

Published: September 12, 2025

Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017.

Journal: Breast cancer (Tokyo, Japan)

Published: August 29, 2025

AdipoR1-AMPK axis suppresses breast cancer across molecular subtypes via multimodal cell death pathways, including ferroptosis and apoptosis.

Journal: Cell death & disease

Published: July 30, 2025

Germline variants of the POLH and RAD51 genes are candidate variants associated with risk of hormone receptor-negative young-onset breast cancer.

Journal: NPJ breast cancer

Published: May 22, 2025